Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of VDJ001 in methotrexate-inadequate-response moderate to severe active rheumatoid arthritis
CTR20244796Phase 3Active
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of VDJ-001 in rheumatoid arthritis (RA), sponsored by Beijing VDJBio Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
VDJ-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20244796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244796.